Seasonal Respiratory Health
1. Definition and Overview
Seasonal respiratory health refers to the capacity of the respiratory system to resist, manage, and recover from the infectious, allergenic, and environmental challenges that recur in predictable seasonal patterns throughout the year. The term encompasses a spectrum of conditions — most prominently upper respiratory tract infections (URTIs) such as the common cold, rhinitis, sinusitis, and pharyngitis — but also extends to lower respiratory complications such as bronchitis and, in more severe cases, pneumonia. From a nutrition and natural-health perspective, the focus is on understanding the physiological, dietary, and environmental factors that modulate susceptibility and resilience to these recurring challenges.
The seasonal cycle of respiratory viral diseases has been widely recognized for thousands of years, as annual epidemics of the common cold and influenza disease hit the human population like clockwork in the winter season in temperate regions. Upper respiratory tract infections are the most common infectious disease cause for patient evaluations worldwide, are typically self-limited, and mild to moderate in severity; the most common manifestation is the common cold.
Viral and bacterial respiratory tract infections are associated with high morbidity and mortality worldwide. In 2021, upper respiratory tract infections alone accounted globally for 12.8 billion episodes of illness and 19,600 deaths, with the highest mortality rates seen in lower-income regions.
2. The Respiratory System: Structures Involved
Seasonal respiratory challenges principally affect two anatomically distinct regions:
- Upper respiratory tract (URT): Upper respiratory tract infections usually involve the nose, sinuses, and throat; examples include the common cold, sinus infection, and sore throat.
- Lower respiratory tract (LRT): Lower respiratory tract infections primarily affect the lungs, with examples including bronchitis and pneumonia.
Beyond the mechanical airways, the immune system is a central participant. Nutrition plays a key role in every stage of the immune response, together with lifestyle factors. The first layer of non-specific innate immunity is of rapid onset — within minutes to hours — and includes the physical barriers such as the skin, mucous membranes, the nasopharynx, and respiratory tract, as well as biochemical reactions and inflammation via inflammatory cytokines. The adaptive immune system, largely mediated by leukocytes, especially B- and T-cells, is slower to mount its response, but the response is highly specific and in some cases may lead to lifelong protection against the invading pathogen.
The mucosal surface of the respiratory tract functions as a primary defense. When a respiratory virus is inhaled it first binds to non-specific receptors on the respiratory epithelium, usually glycolipids or glycoproteins such as intercellular adhesion molecule (ICAM)-1. Disruption of the mucosal barrier — by dry air, cold temperatures, or nutritional deficiencies — facilitates pathogen entry.
3. Seasonal Patterns and Causative Pathogens
Respiratory viruses follow seasonal patterns. Influenza and RSV infections only occur during the winter months, with rhinovirus colds typically observed in the fall and spring. Adenovirus infection appears year-round. Seasonal influenza typically lasts from November until March in the Northern Hemisphere. Coronaviruses spread year-round, with increased activity typically in the fall and winter.
The common cold is most often caused by one of several hundred rhinoviruses (approximately 52%), but coronaviruses (8%) or respiratory syncytial virus (7%) may also lead to infection. Other viruses, such as influenza (6%), parainfluenza, and adenoviruses, may produce respiratory symptoms, but these are often associated with pneumonia, fever, or chills.
The most common respiratory diseases in epidemiological studies are upper respiratory tract infections (URTIs), comprising approximately 82.8% of respiratory cases, followed by asthma (11.5%) and allergic rhinitis (4.5%).
Allergic rhinitis represents a separate but overlapping seasonal phenomenon: allergic rhinitis may be seasonal in response to allergens such as pollen, or perennial, where a major cause is the allergen Der pl in the faeces of the house-dust mite Dermatophagoides pteronyssinus.
4. Contributing and Associated Factors
4.1 Environmental and Meteorological Factors
The two major contributing factors to seasonal respiratory infection patterns are changes in environmental parameters and human behavior. Studies have revealed the effect of temperature and humidity on respiratory virus stability and transmission rates. More recent research highlights the importance of environmental factors, especially temperature and humidity, in modulating host intrinsic, innate, and adaptive immune responses to viral infections in the respiratory tract.
A notable hypothesis in the scientific literature is temperature-dependent viral tropism (TDVT). TDVT proposes that viruses can spread more effectively if they moderate their pathogenicity by developing thermal sensitivity within a range that supports organ-specific viral tropism within the human body, whereby they replicate most rapidly at temperatures below body temperature. This can confine them to the upper respiratory tract and allow them to avoid infecting the lungs, heart, and gut.
4.2 Behavioral and Social Factors
Seasonality of respiratory viral infections is likely affected by multiple factors, including age-dependent human behavioral changes such as school calendars and spending time indoors during colder months, meteorological factors such as humidity and temperature, and climatic influences on host resistance such as sun exposure and related vitamin D levels.
4.3 Host Immune Status
It is well established that nutrition directly impacts immunosenescence because deficiencies in several vitamins and minerals, protein-energy malnutrition, and excessive consumption of saturated fatty acids can hinder immune systems. Age is a further modifier: reduced physical activity with age is a major contributor to "immunosenescence," the age-related immune decline. During the process of aging, a rise in systemic inflammation occurs, termed "inflammaging," which is associated with an increased risk of developing a range of age-related conditions.
4.4 The Gut–Lung Axis
Emerging evidence has implicated the gut microbiome in respiratory immune health through a bidirectional communication pathway termed the gut–lung axis. The lungs have their own flora, which are directly related to the gut flora via bidirectional communication allowing the transport of microbial metabolites and toxins produced by intestinal bacteria through the circulation and lymphatic system. This mutual microbial cross-talk modulates the immune and inflammatory response to infections.
Imbalance in the abundance, diversity, and function of the gut microbiota — known as dysbiosis — has been shown to increase host susceptibility to infections in the lungs, suggesting crosstalk between these organs. This crosstalk is now referred to as the gut–lung axis. Gut microbes modulate pulmonary function through immune mediators, metabolites such as short-chain fatty acids, and direct microbial translocation — pathways that collectively enable intestinal microbial communities to exert profound effects on distant lung tissue.
4.5 Sleep and Circadian Rhythms
Sleep also crucially affects the immune response in humans because sleep deprivation has been reported to decrease immune functions, favoring predisposition to viral infections. Shorter sleep duration is associated with a higher risk for common cold. Mechanistically, several explanations for the enhanced susceptibility to infections induced by reduced sleep have been proposed, including reduced T lymphocyte proliferation, reduced expression of HLA-DR molecules, and changes in CD4+ and CD8+ T lymphocytes, all of which have been observed during partial sleep deprivation.
5. Nutrients: Traditional Use and Scientific Evidence
5.1 Vitamin C (Ascorbic Acid)
Traditional use: Vitamin C has been proposed for treating respiratory infections since it was isolated in the 1930s, and became particularly popular in the 1970s when Nobel laureate Linus Pauling concluded from earlier placebo-controlled trials that vitamin C would prevent and alleviate the common cold.
Scientific evidence: The evidence base for vitamin C in respiratory health is substantial but nuanced. Regular ingestion of vitamin C had no effect on common cold incidence in the ordinary population, based on 29 trial comparisons involving 11,306 participants in the landmark Cochrane review by Hemilä and Chalker (2013). However, effects on duration and severity have shown more consistent signal. A 2023 meta-analysis published in BMC Complementary Medicine and Therapies found that compared to placebo, vitamin C significantly decreased the severity of the common cold by 15% (95% CI 9–21%).
A 2022 systematic review and meta-analysis found that benefits of normal vitamin C supplementation for reducing the duration of respiratory tract illness were supported by meta-analysis findings, although this effect on incidence was statistically insignificant (P = 0.09), and supplementation had no consistent effect on the severity of respiratory illness.
In high-physical-exertion populations, results have been more favorable: a systematic review identified seven trials with military personnel, three with students in crowded lodgings, and two with marathon runners; eight of these trials were double-blind and placebo-controlled. Five small trials found a statistically significant 45–91% reduction in common cold incidence in the vitamin C group, though these trials were short and the participants were under heavy exertion.
Evidence strength: Moderate. Evidence supports a modest reduction in cold duration and severity with regular supplementation; prevention benefit is limited to those under heavy physical stress. Evidence for severe respiratory disease (e.g., pneumonia, ARDS) is preliminary and mixed.
5.2 Vitamin D
Traditional and observational background: Research suggested that vitamin D has a potential role in the prevention of acute respiratory infections by increasing immunity. In some observational studies, it was observed that low vitamin D levels in blood are associated with increased incidence of respiratory tract infections.
Mechanistic basis: Vitamin D enhances innate immunity by inducing antimicrobial peptides such as cathelicidin and β-defensin, and modulates adaptive responses by promoting Th2 differentiation and suppressing pro-inflammatory Th1 pathways.
Scientific evidence: Observational studies predominantly reported statistically significant associations between low vitamin D status and increased risk of both upper and lower respiratory tract infections. Meta-analyses of randomized controlled trials have provided a more heterogeneous picture. One systematic review and meta-analysis found that events of respiratory tract infections were significantly lower in the vitamin D group as compared to the control group (odds ratio = 0.582, 95% CI: 0.417–0.812, P = 0.001).
A major 2017 meta-analysis of individual participant data by Martineau et al. (BMJ), analyzing data from multiple randomized controlled trials, is a central reference in this area; it reported moderate protective effects overall, particularly in those who were vitamin D-deficient at baseline. Despite several positive systematic reviews and meta-analyses, the available experimental evidence related to the effects of vitamin D on acute respiratory tract infection is plagued with heterogeneity and mixed quality, and is therefore insufficient to recommend vitamin D supplementation to the general population as a protective agent against acute respiratory tract infection.
In pediatric populations, a 2025 systematic review and meta-analysis of 17 RCTs including 18,372 participants found that for prevention, some trials reported reductions in the incidence of respiratory infections, particularly with daily supplementation or in vitamin D-deficient populations, whereas others observed no significant effect. For treatment, RCTs examining vitamin D as adjunctive therapy in hospitalized children with acute infections similarly produced divergent results.
Evidence strength: Moderate for prevention among vitamin D-deficient individuals; evidence in vitamin D-sufficient populations is weaker and inconsistent. Results across the full body of RCT literature remain heterogeneous.
5.3 Zinc
Traditional use: Zinc lozenges for cold symptoms entered popular use in the 1980s following early clinical observations that zinc salts might have direct antiviral activity in the upper respiratory mucosa by inhibiting rhinovirus replication.
Scientific evidence: The zinc evidence base is notable but contested regarding analytical methodology. A systematic review and meta-analysis published in the Canadian Medical Association Journal (2012) concluded that moderate quality evidence suggested that orally administered zinc reduced the duration of symptoms of the common cold; however, the evidence of benefit was limited to adults, and even in this patient group uncertainty remained about clinical benefit.
Several meta-analyses have reported stronger effects specifically for zinc acetate lozenges. Five previous meta-analyses concluded that there is strong evidence that zinc lozenges can shorten the duration of colds, with one individual patient data meta-analysis calculating a 37% shortening of colds in adults (95% CI: 27–46%; P = 10−9). Given the evidence of efficacy, common cold patients may consider zinc acetate lozenges within 24 hours of onset of symptoms.
The 2024 Cochrane review on zinc and the common cold (Nault et al.) reached a more cautious conclusion: on the basis of the review, the current evidence is insufficient to provide firm conclusions or recommend zinc supplementation for the prevention or treatment of the common cold. However, this conclusion has been contested on methodological grounds: the Cochrane analysis included both zinc lozenge trials and nasal zinc administration trials as if they were similar treatments; furthermore, one zinc lozenge trial administered 190 mg/day zinc while one nasal zinc trial administered just 0.046 mg/day — pooling two trials with a 4,300-fold difference in dose is not considered meaningful.
Evidence strength: Moderately strong for zinc acetate lozenges (specifically, not systemic zinc supplementation) started within 24 hours of symptom onset in adults. Prevention evidence is weaker. The field is complicated by formulation (acetate vs. gluconate), dose, and timing differences across trials.
6. Herbs and Natural Ingredients: Traditional Use and Scientific Evidence
6.1 Echinacea (Echinacea purpurea and related species)
Traditional use: The E. purpurea species of echinacea was originally discovered by Native Americans in North America, who used the plant medicinally for respiratory tract infections, tooth pain, and snakebite. Its use was subsequently adopted in European herbal medicine, particularly in German-speaking countries, where it remains one of the most widely used herbal preparations for cold prevention and treatment.
Scientific evidence: Echinacea has been among the most extensively studied herbal medicines for URTIs. The evidence is mixed. The NCCIH-funded literature documents that a 2016 systematic review and meta-analysis found that echinacea might have a preventative effect on the incidence of upper respiratory tract infections, but it is unclear whether this benefit is clinically meaningful across all preparations. A large NCCIH-funded trial by Barrett et al. (2010) involving 719 participants found that echinacea did not significantly reduce cold duration or severity compared to placebo.
The efficacy of Echinacea sp. is dubious based on the identified studies; over 2,000 persons were given the treatment, but equal amounts of studies of good quality found positive and negative results.
Evidence strength: Weak to moderate, and highly heterogeneous. Inconsistency across trials is largely attributed to differences between species (E. purpurea vs. E. angustifolia vs. E. pallida), plant parts used (root vs. aerial parts), preparation methods (extract, tincture, tablet), and dosing regimens. The most consistently positive results appear to be associated with E. purpurea preparations used at symptom onset.
6.2 Elderberry (Sambucus nigra)
Traditional use: Although the elderberry species most commonly used for immune support is black elderberry (Sambucus nigra, also known as European elderberry), other species of Sambucus with similar characteristics are sometimes used. Black elderberry has a centuries-long history of use in European folk medicine for fever, cold, and influenza-like illness, primarily as a syrup or decoction prepared from the berries.
Scientific evidence: A 2021 PMC systematic review identified five randomized trials on elderberry for treatment or prevention of viral respiratory illness. Elderberry may not reduce the risk of developing the common cold; it may reduce the duration and severity of colds, but the evidence is uncertain. Elderberry may reduce the duration of influenza, but the evidence is uncertain. Compared to oseltamivir, an elderberry-containing product may be associated with a lower risk of influenza complications and adverse events.
Elderberry may be a safe option for treating viral respiratory illness, and there is no evidence that it overstimulates the immune system. However, the evidence on both benefits and harms is uncertain and information from recent and ongoing studies is necessary to make firm conclusions.
Key limitations of the existing trial base include: the studies were extremely small (three had fewer than 65 participants), short (follow-up periods of 16 days or less), and four out of five were funded by the manufacturer of the product being tested. Additionally, the largest study in this review tested a product that contained a mix of ingredients, including echinacea. Several studies also had problems with selective reporting of outcomes and unreliable research methods.
Evidence strength: Low to moderate, preliminary. Signal for modest reduction of cold and influenza duration exists, but trials are small, short, industry-funded, and methodologically limited. Claims about immune overstimulation (cytokine storm) are not supported by the evidence base.
6.3 N-Acetylcysteine (NAC)
Background: N-acetylcysteine (NAC) was introduced in the 1960s as a mucolytic drug for chronic respiratory diseases. It is a precursor to glutathione, the body's principal endogenous antioxidant, and has both mucolytic and antioxidant mechanisms of action.
Scientific evidence: NAC has the strongest evidence base in chronic respiratory conditions. Large RCTs and meta-analyses collectively support NAC's mucolytic, antioxidant, anti-inflammatory, and anti-infective benefits in COPD. N-acetylcysteine reduces exacerbations consistently across multiple meta-analyses and Cochrane reviews, with approximately a 24–25% reduction.
For acute respiratory infections, the evidence is substantially weaker. Clinical trial evidence for the use of NAC as an antioxidant in influenza and other acute viral respiratory tract infections is very limited. It is therefore difficult to draw any concrete conclusions without evidence from larger trials. Current evidence suggests that NAC administration may help improve outcomes in people with acute respiratory distress syndrome and acute lung injury.
Evidence strength: Strong for chronic obstructive pulmonary disease exacerbations; weak and preliminary for acute upper respiratory infection. Not established as a preventive strategy for seasonal illness in healthy populations.
6.4 Quercetin
Background: Quercetin is a flavonoid polyphenol found in foods such as onions, apples, capers, and berries. It has a history of use in traditional botanical medicine across various cultures as a general-purpose anti-inflammatory and antiviral agent.
Scientific evidence: A systematic review and meta-analysis of preclinical studies assessed quercetin-type flavonols for viral lower respiratory tract infections. The primary evidence base consists of in vitro and animal studies demonstrating antiviral, anti-inflammatory, and antioxidant activity. Human clinical trial data specifically for seasonal respiratory illness is limited. The evidence is currently predominantly preclinical, and robust human RCT data for quercetin in preventing or treating seasonal URTIs remains insufficient to draw firm conclusions.
Evidence strength: Preliminary — primarily in vitro and animal studies. Human clinical evidence for acute seasonal respiratory infections is insufficient at this time.
6.5 Honey
Traditional use: Honey has been used for millennia across many cultures — including Egyptian, Greek, Ayurvedic, and traditional Chinese medicine — as a remedy for cough, sore throat, and respiratory complaints. It is commonly prepared as a warm drink with lemon and ginger.
Scientific evidence: The strongest clinical evidence for honey is in the context of acute cough, particularly in children. A 2018 Cochrane review on honey for acute cough in children found that honey was more effective than placebo, diphenhydramine, and no treatment at reducing cough frequency and severity. In vitro studies have demonstrated antimicrobial activity for manuka and other honeys against respiratory pathogens. However, large-scale RCTs for prevention or treatment of viral respiratory infections in adults remain limited.
Evidence strength: Moderate for symptomatic cough relief, particularly in children; limited for antiviral or preventive effects in adults.
7. Probiotics and the Gut–Lung Axis
The use of probiotics, prebiotics, and synbiotics for modulation of gut microbiota has been studied based on their effectiveness in reducing the duration and severity of respiratory tract infections, mainly owing to their effects on preventing pathogen colonization and modulating the immune system.
Probiotics are live microorganisms that confer benefits to the host when administered in adequate amounts. They are considered important tools for the modulation of microbiota in the gut–lung axis; common mechanisms reported between species include colonization of the respiratory and intestinal tracts, production of short-chain fatty acids and antimicrobial peptides, maintenance of the integrity of the intestinal and pulmonary mucosa, and stimulation of the innate and adaptive immune system.
Preclinical and clinical studies have shown that probiotics can regulate cytokine secretion, thus affecting both nonspecific and specific immunity. Probiotics act by blocking viruses from invading and proliferating in host cells, by stimulating the immune response, and by suppressing the activation of the NLRP3 inflammasome.
A 2015 Cochrane review by Hao, Dong, and Wu on probiotics for preventing acute upper respiratory tract infections found that probiotics were superior to placebo in reducing the number of participants experiencing at least one URTI and in reducing antibiotic use, though the quality of evidence was rated as low to moderate. An exploratory clinical trial investigating a Lactobacillus probiotic blend in asthmatic patients found that asthmatic subjects who took the blend showed significant improvements in lung function as measured by forced expiratory volume and serum short-chain fatty acid levels from baseline to week 4, though due to the lack of a control group, a longer blinded, placebo-controlled study was warranted to confirm these findings.
Evidence strength: Moderate and growing. Specific strains (particularly Lactobacillus and Bifidobacterium species) show promise for reducing URTI incidence, though strain specificity, dosing, and duration remain important variables.
8. Dietary Factors
8.1 Overall Dietary Pattern
The Mediterranean diet is a dietary type that is believed to be rich in balanced micronutrients and considered as one of the healthiest nutritional guidelines. While the health benefits of nutrition and physical activity are frequently studied separately, it is now becoming increasingly clear that combining nutrition and physical activity can produce more significant positive health consequences and boost the immune system.
The major non-communicable diseases, including chronic respiratory diseases, share four modifiable behavioral risk factors: unhealthy diet, physical inactivity, tobacco usage, and excess alcohol consumption. The adoption of healthy lifestyles — including not excessive alcohol intake, no smoking, a healthy diet, and regular physical activity — represents a crucial and economical strategy to counteract this global burden.
8.2 Micronutrient Adequacy
Beyond individual supplementation, dietary adequacy across a range of micronutrients is fundamental to immune competence. It is well established that nutrition directly impacts immunosenescence because deficiencies in several vitamins and minerals, protein-energy malnutrition, and excessive consumption of saturated fatty acids can hinder immune systems. Key micronutrients with established immune roles include vitamin C (from fruits and vegetables), vitamin D (from oily fish, eggs, and fortified foods, supplemented as needed), zinc (from meat, shellfish, legumes, and seeds), selenium, and iron.
9. Lifestyle Factors
9.1 Physical Activity
Regular moderate exercise has been shown to reduce the risk of infection compared to a sedentary lifestyle. Regular physical activity has been associated with reduced systemic inflammation in the elderly, and evidence demonstrates that reduced physical activity with age is a major contributor to immunosenescence, the age-related immune decline. It is important to note that the evidence base specifically concerns moderate exercise; very high-intensity or prolonged exercise has been associated with a transient window of increased infection susceptibility in athletes, as reflected in the heavy-exertion populations where vitamin C showed the strongest benefit.
9.2 Sleep Quality and Duration
Data suggest that sleep is required for a functional immune system to face respiratory viral or bacterial infections. Nocturnal sleep is an essential physiological function whose alteration is associated with health outcomes and chronic diseases. Scientific evidence suggests that diet and sleep are related in a bidirectional relationship.
Sleep deprivation also perturbs the gut microbiome, with downstream implications for respiratory immunity: sleep deprivation depletes the number of specific beneficial bacteria such as probiotics and increases the quantity of some pathogenic bacteria, which may cause diseases and illnesses.
9.3 The Mediterranean Lifestyle Cluster
The scientific literature increasingly frames respiratory immune health not in terms of isolated nutrients but in terms of integrated lifestyle clusters. The Mediterranean diet, as described in the Seven Countries' Study and subsequent research, is part of a healthy lifestyle pattern that includes preference for seasonal, local, fresh, and raw foods; eating with moderation; conviviality and social interactions; leisure activities such as moderate physical activity; adequate and regular nocturnal sleep according to the circadian sleep–wake rhythm; and a less stressful way of life. The Mediterranean diet is well known for its protective effects against noncommunicable diseases and overall mortality, thanks to its anti-inflammatory, antioxidant, and neuroprotective properties.
9.4 Smoking and Alcohol
Tobacco smoking is a well-established impairment of mucosal respiratory defenses and is recognized across authoritative sources as one of the primary modifiable risk factors for respiratory infections and chronic respiratory disease. Excess alcohol consumption similarly impairs immune function, both through direct immunosuppressive effects and by disrupting gut microbiota integrity — relevant to the gut–lung axis mechanisms described above.
10. Summary of Evidence Levels
- Vitamin C: Robust evidence for modest reduction in cold duration (1–1.5 days); stronger prevention effect in individuals under heavy physical exertion; no prevention benefit in the general population.
- Vitamin D: Consistent observational associations between deficiency and infection risk; RCT evidence supports benefit primarily in deficient individuals; overall evidence heterogeneous.
- Zinc (lozenges, acetate form): Moderately strong evidence for reducing cold duration in adults when started within 24 hours of symptom onset; prevention evidence weaker; evidence contested across reviews due to methodological disagreements.
- Echinacea: Mixed and weak-to-moderate evidence; inconsistency driven by species, preparation, and timing variation; possible prevention signal with E. purpurea.
- Elderberry: Low-to-moderate evidence; possible modest reduction in cold and flu duration and severity; trials small, short, and often industry-funded.
- NAC: Strong evidence for chronic respiratory disease (COPD exacerbation prevention); very limited evidence for acute seasonal infection.
- Probiotics: Moderate and growing evidence for URTI incidence reduction via the gut–lung axis; strain specificity is important.
- Quercetin: Primarily preclinical evidence; insufficient human trial data.
- Honey: Moderate evidence for symptomatic cough relief; limited for antiviral prevention.
- Sleep, moderate exercise, and Mediterranean dietary pattern: Consistent supportive evidence from epidemiological and physiological research.
References
Go back